Patients with presyncope and those with syncope in the ED have similar 30‑day serious cardiac outcomes, although patients ...
Weekly hydrocolloid dressings were comparable to a daily petroleum-based regimen for patient-reported scar appearance after ...
CNW/ - Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada has approved LYVDELZI (seladelpar) for the ...
Cannabis users experienced similar transplant evaluation and posttransplant outcomes as nonusers, indicating cannabis use ...
(Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI ® (enzalutamide), in combination with leuprolide ...
Zacks Investment Research on MSN
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study
Sanofi SNY announced that the phase II ElevAATe study, which evaluated its pipeline candidate, efdoralprin alfa, for the ...
Polypills for HFrEF are being tested in RCTs, and if they’re approved, experts want to be ready for their rollout and use.
KEYTRUDA is indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then ...
At the end of the day, all runners want to get better at their sport and prevent injury. Symmetry plays a crucial role in ...
AZoCleantech on MSN
China’s End-of-Life Trucks Hold Potential for Sustainable Resource Recovery, Study Finds
China's retired trucks hold valuable metals. Strengthening recycling systems is crucial to prevent pollution and harness ...
The Food and Drug Administration (FDA) has approved Gazyva ® (obinutuzumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback